Loading clinical trials...
Loading clinical trials...
The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
GlaxoSmithKline
NCT06894212 · Schizophrenia
NCT06003036 · Schizophrenia, Schizoaffective Disorder
NCT04226898 · Schizophrenia, Schizoaffective Disorder
NCT05240976 · Schizophrenia
NCT06745479 · Schizophrenia, Schizoaffective Disorder, and more
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Cerritos, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions